FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2727 December 18, 2008 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sherman, S. I. PubMed Citation

To the Editor: Sherman et al. (July 3 issue)¹ highlight the importance of selecting patients for alternative therapies, such as motesanib diphosphate, in the treatment of progressive differentiated thyroid carcinomas. Although radiographic findings are useful criteria for predicting a response to motesanib, they can be supplemented by the microscopical findings — in particular, growth pattern, necrosis, and desmoplastic reaction — which have been correlated with progression prediction.² The genotypic alterations described in follicular-cell neoplasms control the mitogen-activated protein (MAP) kinase pathway and proliferation. Was any correlation found with proliferation markers? Which radiographic criteria were used to define progression in metastatic . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.